Related references
Note: Only part of the references are listed.Final overall survival (OS) results from SOLO2/ENGOT-ov21: A phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation.
Andres Poveda et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Imidazo[1,2-a]pyridine Derivatives as Aldehyde Dehydrogenase Inhibitors: Novel Chemotypes to Target Glioblastoma Stem Cells
Luca Quattrini et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Progress in the Field of Aldehyde Dehydrogenase Inhibitors: Novel Imidazo[1,2-a]pyridines against the 1A Family
Luca Quattrini et al.
ACS MEDICINAL CHEMISTRY LETTERS (2020)
A Pan-ALDH1A Inhibitor Induces Necroptosis in Ovarian Cancer Stem-like Cells
Ilana Chefetz et al.
CELL REPORTS (2019)
Aldehyde Dehydrogenase Inhibitors for Cancer Therapeutics
Saketh S. Dinavahi et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2019)
Engineered 3D Model of Cancer Stem Cell Enrichment and Chemoresistance
Maria R. Ward Rashidi et al.
NEOPLASIA (2019)
Discovery of Orally Bioavailable, Quinoline-Based Aldehyde Dehydrogenase 1A1 (ALDH1A1) Inhibitors with Potent Cellular Activity
Shyh-Ming Yang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Structure-Based Optimization of a Novel Class of Aldehyde Dehydrogenase 1A (ALDH1A) Subfamily-Selective Inhibitors as Potential Adjuncts to Ovarian Cancer Chemotherapy
Brandt C. Huddle et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Structural Basis of ALDH1A2 Inhibition by Irreversible and Reversible Small Molecule Inhibitors
Yan Chen et al.
ACS CHEMICAL BIOLOGY (2018)
Bevacizumab in ovarian cancer: A critical review of phase III studies
Luigi Rossi et al.
ONCOTARGET (2017)
PARP inhibitors: Clinical utility and possibilities of overcoming resistance
Benjamin G. Bitler et al.
GYNECOLOGIC ONCOLOGY (2017)
Inhibition of the Aldehyde Dehydrogenase 1/2 Family by Psoralen and Coumarin Derivatives
Cameron D. Buchman et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Combating subclonal evolution of resistant cancer phenotypes
Samuel W. Brady et al.
NATURE COMMUNICATIONS (2017)
Personalized Medicine-Based Approach to Model Patterns of Chemoresistance and Tumor Recurrence Using Ovarian Cancer Stem Cell Spheroids
Shreya Raghavan et al.
CLINICAL CANCER RESEARCH (2017)
FOXD1-ALDH1A3 Signaling Is a Determinant for the Self-Renewal and Tumorigenicity of Mesenchymal Glioma Stem Cells
Peng Cheng et al.
CANCER RESEARCH (2016)
BET Inhibitors Suppress ALDH Activity by Targeting ALDH1A1 Super-Enhancer in Ovarian Cancer
Yuhki Yokoyama et al.
CANCER RESEARCH (2016)
ALDH1A3, the Major Aldehyde Dehydrogenase Isoform in Human Cholangiocarcinoma Cells, Affects Prognosis and Gemcitabine Resistance in Cholangiocarcinoma Patients
Ming-Huang Chen et al.
CLINICAL CANCER RESEARCH (2016)
ALDH1A3, a metabolic target for cancer diagnosis and therapy
Jiang-Jie Duan et al.
INTERNATIONAL JOURNAL OF CANCER (2016)
The current status of PARP inhibitors in ovarian cancer
Jennifer McLachlan et al.
TUMORI JOURNAL (2016)
Aldehyde dehydrogenase 1A1 in stem cells and cancer
Hiroyuki Tomita et al.
ONCOTARGET (2016)
Comparative analysis of tumor spheroid generation techniques for differential in vitro drug toxicity
Shreya Raghavan et al.
ONCOTARGET (2016)
The current status of PARP inhibitors in ovarian cancer
Jennifer McLachlan et al.
TUMORI JOURNAL (2016)
Crystal structure of human aldehyde dehydrogenase 1A3 complexed with NAD+ and retinoic acid
Andrea Moretti et al.
SCIENTIFIC REPORTS (2016)
N,N-diethylaminobenzaldehyde (DEAB) as a substrate and mechanism-based inhibitor for human ALDH isoenzymes
Cynthia A. Morgan et al.
CHEMICO-BIOLOGICAL INTERACTIONS (2015)
Characterization of Two Distinct Structural Classes of Selective Aldehyde Dehydrogenase 1A1 Inhibitors
Cynthia A. Morgan et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Discovery of NCT-501, a Potent and Selective Theophylline-Based Inhibitor of Aldehyde Dehydrogenase 1A1 (ALDH1A1)
Shyh-Ming Yang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
β-Catenin-regulated ALDH1A1 is a target in ovarian cancer spheroids
S. Condello et al.
ONCOGENE (2015)
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
David D. Bowtell et al.
NATURE REVIEWS CANCER (2015)
Cisplatin-resistant cells in malignant pleural mesothelioma cell lines show ALDHhighCD44+ phenotype and sphere-forming capacity
Lourdes Cortes-Dericks et al.
BMC CANCER (2014)
Development of Selective Inhibitors for Human Aldehyde Dehydrogenase 3A1 ( ALDH3A1) for the Enhancement of Cyclophosphamide Cytotoxicity
Bibek Parajuli et al.
CHEMBIOCHEM (2014)
Conformational restriction: an effective tactic in 'follow-on'-based drug discovery
Zengjun Fang et al.
FUTURE MEDICINAL CHEMISTRY (2014)
ALDH Maintains the Stemness of Lung Adenoma Stem Cells by Suppressing the Notch/CDK2/CCNE Pathway
Zhongjun Li et al.
PLOS ONE (2014)
ALDH-positive lung cancer stem cells confer resistance to epidermal growth factor receptor tyrosine kinase inhibitors
Cheng-Po Huang et al.
CANCER LETTERS (2013)
Lipophilic efficiency: the most important efficiency metric in medicinal chemistry
Kevin D. Freeman-Cook et al.
FUTURE MEDICINAL CHEMISTRY (2013)
Characterization of aldehyde dehydrogenase isozymes in ovarian cancer tissues and sphere cultures
Yu-Ting Saw et al.
BMC CANCER (2012)
Inhibition of aldehyde dehydrogenase (ALDH) activity reduces chemotherapy and radiation resistance of stem-like ALDHhiCD44+ human breast cancer cells
Alysha K. Croker et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Expression of aldehyde dehydrogenase and CD133 defines ovarian cancer stem cells
Ilona Kryczek et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
Aldehyde dehydrogenase 1A1 confers intrinsic and acquired resistance to gemcitabine in human pancreatic adenocarcinoma MIA PaCa-2 cells
Hong-Quan Duong et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2012)
Indole-2-carboxamides as Allosteric Modulators of the Cannabinoid CB1 Receptor
Francesco Piscitelli et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
ALDH1A Isozymes are Markers of Human Melanoma Stem Cells and Potential Therapeutic Targets
Yuchun Luo et al.
STEM CELLS (2012)
Aldehyde Dehydrogenase Inhibitors: a Comprehensive Review of the Pharmacology, Mechanism of Action, Substrate Specificity, and Clinical Application
Vindhya Koppaka et al.
PHARMACOLOGICAL REVIEWS (2012)
Aldehyde Dehydrogenase in Combination with CD133 Defines Angiogenic Ovarian Cancer Stem Cells That Portend Poor Patient Survival
Ines A. Silva et al.
CANCER RESEARCH (2011)
First-Line Therapy in Ovarian Cancer Trials
Tate Thigpen et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2011)
Integrated genomic analyses of ovarian carcinoma
D. Bell et al.
NATURE (2011)
Greener Friedel-Crafts Acylations: A Metal- and Halogen-Free Methodology
Mark C. Wilkinson
ORGANIC LETTERS (2011)
Aldehyde Dehydrogenase Activity of Breast Cancer Stem Cells is Primarily Due to Isoform ALDH1A3 and Its Expression is Predictive of Metastasis
Paola Marcato et al.
STEM CELLS (2011)
Conformer Generation with OMEGA: Algorithm and Validation Using High Quality Structures from the Protein Databank and Cambridge Structural Database
Paul C. D. Hawkins et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2010)
Targeting Aldehyde Dehydrogenase Cancer Stem Cells in Ovarian Cancer
Charles N. Landen et al.
MOLECULAR CANCER THERAPEUTICS (2010)
High ALDH Activity Identifies Chemotherapy-Resistant Ewing's Sarcoma Stem Cells That Retain Sensitivity to EWS-FLI1 Inhibition
Ola Awad et al.
PLOS ONE (2010)
Escape from Flatland: Increasing Saturation as an Approach to Improving Clinical Success
Frank Lovering et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
ALDH isozymes downregulation affects cell growth, cell motility and gene expression in lung cancer cells
Jan S. Moreb et al.
MOLECULAR CANCER (2008)
Aldehyde dehydrogenase discriminates the CD133 liver cancer stem cell populations
Stephanie Ma et al.
MOLECULAR CANCER RESEARCH (2008)
Colorectal Cancer Stem Cells Are Enriched in Xenogeneic Tumors Following Chemotherapy
Scott J. Dylla et al.
PLOS ONE (2008)
Facile reduction of malonate derivatives using NaBH4/Br2:: an efficient route to 1,3-diols
Matthew Tudge et al.
TETRAHEDRON LETTERS (2008)
Optimal description of a protein structure in terms of multiple groups undergoing TLS motion
J Painter et al.
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY (2006)
A convenient method for the preparation of alkyl aryl sulfides from alcohols and (chloromethylene)dimethylammonium chloride
Y Kawano et al.
CHEMISTRY LETTERS (2005)
A novel method for the synthesis of imidazo[5,1-f][1,2,4]triazin-4(3H)-ones
A Heim-Riether et al.
JOURNAL OF ORGANIC CHEMISTRY (2005)
A molecular viewer for the analysis of TLS rigid-body motion in macromolecules
J Painter et al.
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY (2005)
Cancer of the ovary
SA Cannistra
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Coot:: model-building tools for molecular graphics
P Emsley et al.
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY (2004)
Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study
RF Ozols et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Multiple conformations of NAD and NADH when bound to human cytosolic and mitochondrial aldehyde dehydrogenase
PK Hammen et al.
BIOCHEMISTRY (2002)
Direct reduction of alcohols: Highly chemoselective reducing system for secondary or tertiary alcohols using chlorodiphenylsilane with a catalytic amount of indium trichloride
M Yasuda et al.
JOURNAL OF ORGANIC CHEMISTRY (2001)
Novel azo derivatives as prodrugs of 5-aminosalicylic acid and amino derivatives with potent platelet activating factor antagonist activity
E Carceller et al.
JOURNAL OF MEDICINAL CHEMISTRY (2001)
Share Paper
